Mitotic kinesin inhibitors

a technology of kinesin inhibitors and mitotic kinesins, which is applied in the field of cycloalkylpyrimidinone derivatives, can solve the problems of limiting the usefulness of drugs, inducing cancer cell death, and inhibiting cancer cell division

Inactive Publication Date: 2005-05-19
FRALEY MARK +1
View PDF0 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The present invention relates to cycloalkylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating

Problems solved by technology

It is presumed that disruption of the mitotic spindle by these drugs results in inhibition of cancer cell division, and induction of cancer cell death.
Because these agents do not specifically target mitotic spindles, they have side effects that limit their usefulness.
Experimental perturbation of mitotic kinesin function causes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mitotic kinesin inhibitors
  • Mitotic kinesin inhibitors
  • Mitotic kinesin inhibitors

Examples

Experimental program
Comparison scheme
Effect test

examples

[0429] Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be illustrative of the invention and not limiting of the reasonable scope thereof.

3-benzyl-2-propyl-3,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one (1-2)

[0430] To a flame dried flask equipped with stir bar was added ethyl 2-amino cyclopentenecarboxylic acid (1-1, 0.49 g, 3.2 mmol) and 1,1,1-trimethoxybutane (1.0 mL, 6.3 mmol). The resulting solution was treated with 3 drops of acetic acid and stirred at 25° C. for 12 hours, and then 50° C. for 2 hours. The reaction was diluted with EtOAc (10 mL), washed with 5% aqueous NaHCO3 and the organic layer was separated. The combined organics were dried over magnesium sulfate, filtered and concentrated. The crude oil was then dissolved in MeOH (10 mL) and treated with benzyl amine (2.1 mL, 19.7 mmoL). The reaction was heated to reflux under a condenser for 12 hours. The react...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention relates to cycloalkylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

Description

BACKGROUND OF THE INVENTION [0001] This invention relates to cycloalkylpyrimidinone derivatives that are inhibitors of mitotic kinesins, in particular the mitotic kinesin KSP, and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation. [0002] Therapeutic agents used to treat cancer include the taxanes and vinca alkaloids. Taxanes and vinca alkaloids act on microtubules, which are present in a variety of cellular structures. Microtubules are the primary structural element of the mitotic spindle. The mitotic spindle is responsible for distribution of replicate copies of the genome to each of the two daughter cells that result from cell division. It is presumed that disruption of the mitotic spindle by these drugs results in inhibition of cancer cell division, and induction of cancer cell death. However, microtubules form other types of cellular structures, including tracks for...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/138A61K31/395A61K31/4465A61K31/4535A61K31/517A61K31/519A61K31/5377A61K31/541A61K31/5513A61K39/395A61K45/00A61P35/00A61P43/00C07D239/70C07D401/06C07D401/12C07D401/14C07D403/06C07D403/14C07D413/14C07D417/14C07D487/10
CPCC07D239/70C07D401/06C07D403/06C07D401/14C07D401/12A61P35/00A61P43/00
Inventor FRALEY, MARKGARBACCIO, ROBERT
Owner FRALEY MARK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products